Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 2, March-April, p. 277–280

doi: 10.17219/acem/63006

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Serum carnitine and acyl-carnitine in patients with meningitis due to tick-borne encephalitis virus infection

Alina Kępka1,A,B,C,D,F, Roman M. Janas1,C,E,F, Sławomir A. Pancewicz2,A,C,F, Renata Świerzbińska2,B,F

1 Department of Biochemistry, Radioimmunology and Experimental Medicine, the Children’s Memorial Health Institute, Warszawa, Poland

2 Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Poland


Background. Hard ticks are the main vectors of tick-borne encephalitis virus (TBEV). Free carnitine (FC) and acylcarnitines (AC) have the basic role in β-oxidation as well as the modulation of immune and nervous system. Homeostasis of carnitines in the TBE patients was not studied so far.
Objectives. This study aimed to evaluate FC and AC serum concentrations in patients with meningitis due to TBEV infection before and after 14 ± 3 days of treatment.
Material and Methods. The study was performed in 14 patients aged 48 ± 29 years that were divided a posteriori (based on their FC level before and after treatment) into 2 subgroups: 1–8 and 9–14. Diagnosis was based on the neurological, serological and pleocytosis evaluation.
Results. The FC level in patients 1–8 before treatment (24.1 ± 8.1) was significantly lower than in patients post-treatment (34.4 ± 8.3), lower than in the control group (40.5 ± 7.6), and lower than in patients 9–14 before treatment (40.0 ± 13.5) but not lower than in the patients 9–14 after treatment (24.7 ± 7.3 μmol/L), respectively, p < 0.05. AC concentration in the patients 1–8 before treatment (4.7 ± 2.2) was apparently lower than in patients post-treatment (9.5 ± 3.9 μmol/L) but the values were not significantly different. In patients 9–14 before treatment the AC concentration (16.3 ± 12.6) was higher than in patients after treatment (5.3 ± 4.0 μmol/L), but the difference was not statistically significant.
Conclusion. FC and AC homeostasis in circulation was disturbed in the patients with meningitis due to TBEV infection patients. The mean levels of FC and AC in 60% of the patients were below the normal range but normalized after treatment whereas in 40% of the patients they were near or at a normal range and significantly decreased after treatment. Explanation of this intriguing finding and its clinical significance is not easy without further studies.

Key words

carnitine deficiency, tick-borne encephalitis, free carnitine, acyl-carnitine

References (10)

  1. Lani R, Moghaddam E, Haghani A, Chang LY, AbuBakar S, Zandi K. Tick-borne viruses: A review from the perspective of therapeutic approach-es. Ticks Tick Borne Dis. 2014;5:457–465.
  2. Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine. 2003; 21 Suppl 1:36–40.
  3. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371: 1861–1871.
  4. Famularo G, De Simone C, Trinchieri V, Mosca L. Carnitines and its congeners: A metabolic pathway to the regulation of immune response and inflammation. Ann N Y Acad Sci. 2004;1033:132–138.
  5. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab (Lond). 2010;7:30–34.
  6. Madiraju P, Pande SV, Prentki M, Madiraju SR. Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. Epige-netics. 2009;4:399–403.
  7. Ribas GS, Vargas CR, Wajner M. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene. 2014;533:469–476.
  8. Jones LL, McDonald DA, Borum PR. Acylcarnitines: Role in brain. Prog Lipid Res. 2010; 49:61–75.
  9. Kępka A, Minarowska A, Minarowski Ł, et al. Serum and urinary carnitine in children with cystic fibrosis. Prog Health Sci. 2013;3:13–18.
  10. Cederblad G, Harper P, Lindgren K. Spectrophotometry of carnitine in biological fluids and tissue with a Cobas Bio centrifugal analyzer. Clin Chem. 1986;322:342–346.